MELDEQ: An alternative Model for End‐Stage Liver Disease score for patients with hepatocellular carcinoma
Michael R. Marvin, Nicole Ferguson, Robert M. Cannon, Christopher M. Jones, Guy N. Brock – 18 February 2015 – Multiple studies have demonstrated an advantage for hepatocellular carcinoma (HCC) patients under the current liver allocation system, such that the United Network for Organ Sharing (UNOS) recently voted in support of a proposal to delay granting Model for End‐Stage Liver Disease (MELD) exception points to all HCC patients for 6 months, independently of a candidate's native MELD score or alpha‐fetoprotein (AFP) level.